46results about How to "Break immune tolerance" patented technology

The invention discloses epitope for an NY-ESO-1 tumor antigen. The amino acid sequence of the mimic epitope is Ser-Leu-Leu- Met-Phe-Ile-Thr-Trp-Cys, namely SLLMFITWC; the mimic epitope can raise a CTL immunity response, can undergo a cross reaction with a natural epitope, has the characteristics of strong immunogenicity, immune tolerance breaking, strong specificity, safety, low cost, and easy synthesis and storage, and can be used to prepare tumor-therapeutic polypeptide vaccine. The invention also discloses a method for predicting the mimic epitope, which comprises steps of the establishment of a structural model of a TCR-pMHC complex, the analysis of TCR binding sites of the epitope, and the analysis of amino acid replacement of the TCR binding sites of the epitope. The method is also applicable to the computer-aided modification of CTL epitopes of other antigens, and can provide a useful tool for the design and research of therapeutic polypeptide vaccine.

The invention relates to an immunogene therapeutic drug for chronic hepatitis B and a preparation method for the immunogene therapeutic drug. The active component of the drug is a replication-competent recombinant vector pSVK-dSFValpha-IRES-hIL-12 (for short, pSVK-HBVE), which is constructed by taking a pSVK carrier as a starting carrier and carries a fusion gene dSFValpha-IRES-hIL12. An antibody targeting interferon alpha and human IL-12 are co-expressed in the replication-competent recombinant vector pSVK to construct a humanized HBsAg dsFv antibody, human interferon-alpha and interleukin-12 fusion expression vector pSVK-dSFValpha-IRES-hIL-12, the fusion expression vector is efficiently expressed in an eukaryotic cell and in vitro, the combined application of human IL-12 and human IFN-alpha has an important synergistic effect during the tumor control process, and a safe and efficient immunogene therapeutic drug is provided for gene therapy of chronic hepatitis B.

The invention discloses a method for preparing a tumor-specific DC vaccine by applying CD34+ cells in umbilical cord blood. The method comprises (1) a step of preparing autologous tumor-related holoantigen; (2) a step of obtaining the umbilical cord blood; (3) a step of obtaining mononuclear cells derived from the umbilical cord blood; (4) a step of purifying CD34+ cells in the mononuclear cells derived from the umbilical cord blood; (5) performing induction culture for a precursor DC; (6) a step of performing amplification and culture of an immature DC; and (7) a step of preparing the DC vaccine.

The invention relates to a medicine for treating and / or preventing cancer and an application. The medicine of the invention includes a recombinant MUC1-MBP fusion protein vaccine and a PD-1 antibody.The medicine is expected to break an immune tolerance state of a tumor microenvironment in vivo and enhance the MUC1 specific anti-tumor immune response, and is expected to completely clear tumors tobring gospel to the majority of cancer patients.

The invention discloses a preparation of traditional Chinese medicines for treating chronic hepatitis B, which is prepared by the following components according to weight percentage: 6-12 percent of Chinese ephedra, 3-9 percent of monkshood, 3-6 percent of asarum, 6-9 percent of dried ginger, 12 percent of Chinese honeylocust spine, 15-30 percent of white backleaf mallotus root, 11-13 percent of Chinese atractylodes, 11-13 percent of radix bupleuri, 14-16 percent of bitter orange, 8-10 percent of peach seed, 8-10 percent of safflower, 29-31 percent of radix astragali, 14-16 percent of angelica, 12-18 percent of herba epimedii and 3-6 percent of scolopendra. In the invention, Chinese medicine treatment is adopted in the early period to positively cure the disease, adjust immunity function of HBV infection patients, excite the immunity of the organism of chronic HBV carriers, break the state of immune tolerance and adjust the immunity function of the patients who suffer from HBeAg masculine minor chronic hepatitis B, thus improving clinical symptoms and physical sign of the two patients, shortening the course of disease of the patients and increasing the negative turning rate of HBeAg and HBV-DNA thereof, therefore, clinical curative effect on treating patients infected by HBV with the traditional Chinese medicine is improved and the curative effect on hepatitis B is enhanced.

The present disclosure is directed to peptide immunogen constructs targeting portions of Calcitonin Gene-Related Peptide (CGRP), compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed peptide immunogen constructs have more than about 30 amino acids and contain (a) a B cell epitope having about more than about 7 contiguous amino acid residues from the CGRP receptor binding or activation regions of the full-length CGRP protein; (b) a heterologous Th epitope; and (c) an optional heterologous spacer. The disclosed CGRP peptide immunogen constructs stimulate the generation of highly specific antibodies directed CGRP for the prevention and / or treatment of migraine.

The invention discloses an immunoenhancer, an immunotherapy medicine composition, a preparation method of the immunotherapy medicine composition and an application of the immunoenhancer and the immunotherapy medicine composition. The immunoenhancer at least comprises interferon and granular cell-macrophage colony stimulating factors, and the immunotherapy medicine composition at least comprises antigen and the immunoenhancer. The immunoenhancer can remarkably enhance the immunity of a body and improve the antigen presenting efficiency of the body, so that the body can establish effective immune activation and response. Strong antibody and cellular immune protection reaction and pathogen removing capacity can be generated, and the immunoenhancer can be applied to therapy of diseases and tumors caused by microorganisms such as viruses and bacteria.

The invention discloses a method for preparing a tumor-specific DC vaccine by applying mononuclear cells of umbilical cord blood. The method comprises (1) a step of preparing autologous tumor-related holoantigen; (2) a step of obtaining the umbilical cord blood; (3) a step of obtaining the mononuclear cells derived from the umbilical cord blood; (4) a step of performing induction culture for a precursor DC of the mononuclear cells derived from the umbilical cord blood; (5) a step of performing amplification and culture of an immature DC; and (6) a step of preparing the DC vaccine.

The invention discloses a method for preparing a tumor-specific DC vaccine by applying CD34+ cells in umbilical cord blood. The method comprises (1) a step of preparing autologous tumor-related holoantigen; (2) a step of obtaining the umbilical cord blood; (3) a step of obtaining mononuclear cells derived from the umbilical cord blood; (4) a step of purifying CD34+ cells in the mononuclear cells derived from the umbilical cord blood; (5) performing induction culture for a precursor DC; (6) a step of performing amplification and culture of an immature DC; and (7) a step of preparing the DC vaccine.

The invention discloses a therapeutic DC compound vaccine against herpes simplex virus and a preparation method thereof, comprising three kinds of dendritic cells loaded with HSV-2 virus-specific immune antigen gene fragments modified, and the three kinds of HSV-2 virus-specific immune antigen gene fragments loaded with dendritic cells The gene fragments of sexual immune antigens were gC+US10, DC‑UL47, and gD+ICP4, respectively. The present invention uses the granulocyte-macrophage cluster factor receptor signal peptide to guide the expression of the antigen, which can improve the expression efficiency of the antigen, enhance its immune effect, and generate a stronger anti-HSV specific immune response.

The present invention provides a peptide having high binding affinity for PD-L1 protein and use thereof. The peptide has an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 4, or the peptide is a tandem or branched peptide with a single repeat or multiple repeats of SEQ ID NO: 1, SEQ ID NO: 3 and SEQ ID NO: 4 and has an amino acid sequence of SEQ ID NO: 5. The peptide can bind to human PD-L1 with high affinity, competitively block the affinity of PD-1 / PD-L1 protein, block the negative regulatory tolerance pathway of human tumors, activate immunity and increase the lethality of T cells against tumor cells.